Altimmune

Clinical-stage biopharmaceutical company, developing peptide therapeutics for obesity and liver diseases.

Doctor holding a vial of medicine in the laboratory

Altimmune is a clinical-stage vaccine development company headquartered in Gaithersburg, Maryland, US. 

Moving to advance its leadership in developing vaccines for important public health and biodefence needs, Altimmune Inc announced in 2015 that it had entered into a definitive agreement to acquire Immune Targeting Systems (ITS) Ltd. ITS develops novel T-cell vaccines at its operations in the UK and France. 

The deal is an all-stock transaction and the combined company will be known as Vaxin Inc.

Dr. Harriet Story (away from office)

Senior Business Manager

Dr Story joined us in 2019, covering the UCL School of Pharmacy, the Institute of Liver and Digestive Health, and the Centre for Rheumatology. She spent time co-representing the joint interests of UCL Ventures and Cancer Research UK as a cancer specialist, but is now solely a UCL Ventures employee.

Harriet joined us from Imperial Innovations, where she provided intellectual property and commercialisation services to four partner NHS Trusts: Imperial College Healthcare NHS Trust, Royal Brompton & Harefield NHS Foundation Trust, Chelsea and Westminster Hospital NHS Foundation Trust and London North West University Healthcare NHS Trust.

Prior to her career in technology transfer, she worked on a drug discovery project at CRUK’s Therapeutic Discovery Labs (TDL, previously known as CRT) and completed her interdisciplinary PhD at UCL with applications in cancer imaging and treatment.